Sugi Predict

Sugi Predict / Compounds / SCHEMBL23326804

SCHEMBL23326804

SCHEMBL23326804

CC(=O)c1cc(N)cc(C(F)(F)F)c1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KIF11 P52732 2/20 0.38
▸ GLA P06280 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ PTGS1 P23219 1/20 0.37
▸ CFTR P13569 3/20 0.36
▸ KDM4E B2RXH2 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ CES2 O00748 2/20 0.33
▸ AKR1C3 P42330 1/20 0.32
▸ AKR1C2 P52895 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ HTR2A P28223 1/20 0.32
▸ HTR2C P28335 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24566862 0.84 KDM4E (0.43) GLAPOLBGAATSHRPTGS1
SCHEMBL24566861 0.81 CFTR (0.44) GLAPOLBGAATSHRPTGS1
SCHEMBL18354453 0.80 KIF11 (0.39) KIF11POLBGAAMEN1KMT2A
SCHEMBL16637355 0.78 KDM4E (0.47) GAATSHRKDM4EMEN1KMT2A
SCHEMBL24566864 0.77 HDAC4 (0.34) GLAPOLBGAATSHRPTGS1
SCHEMBL19461248 0.76 GAA (0.52) KIF11GLAPOLBGAATSHR
SCHEMBL18160484 0.76 PTGS1 (0.48) KIF11GLAPOLBGAATSHR
Hydrochloric Acid SCHEMBL19461409 0.75 GAA (0.50) KIF11GLAPOLBGAATSHR
SCHEMBL23521067 0.73 MEN1 (0.44) GAAMEN1KMT2AMAPTAKR1C3
SCHEMBL31643059 0.71 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4620531-A2 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. (US) 2025-09-24 — — EP disclosed
US-20250270220-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-08-28 — — US disclosed
WO-2025137507-A1 SOS1 INHIBITORS AND USES THEREOF REGOR PHARMACEUTICALS, INC. (US) 2025-06-26 — — WO disclosed
US-12304915-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2025-05-20 — — US disclosed
US-12258366-B2 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2025-03-25 — — US disclosed
CN-119462626-A SOS1 inhibitors 米拉蒂治疗股份有限公司 2025-02-18 — — CN disclosed
CN-115135315-B SOS1 inhibitors 米拉蒂治疗股份有限公司 2024-11-26 — — CN disclosed
US-20240208945-A1 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES MEDSHINE DISCOVERY INC. (CN) 2024-06-27 — — US disclosed
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-11-16 — — US disclosed
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-11-16 — — US disclosed
EP-4076418-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2022-10-26 — — EP disclosed
CN-115135315-A SOS1 inhibitors 米拉蒂治疗股份有限公司 2022-09-30 — — CN disclosed
EP-4055017-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. (US) 2022-09-14 — — EP disclosed
CN-114901662-A Bicyclic heteroaryl compounds and uses thereof 锐新医药公司 2022-08-12 — — CN disclosed
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2021-11-09 — — US disclosed
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2021-11-09 — — US disclosed
US-20210188857-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. 2021-06-24 — — US disclosed
US-20210188857-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. 2021-06-24 — — US disclosed
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. 2021-05-13 — — US disclosed
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. 2021-05-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12304915-B2 SOS1 inhibitors SOS1, SOS2, SAV1 KIF11 2975/4885GLA 1947/4885POLB 3766/4885
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof SOS1, SOST, SOS2 KIF11 4752/4885GLA 1353/4885POLB 3905/4885
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 KIF11 4867/4885GLA 893/4885POLB 3902/4885
US-20240208945-A1 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES CYP3A7, UGT2B7, CYP51A1 KIF11 2155/4885GLA 1688/4885POLB 3068/4885
US-20250270220-A1 SOS1 INHIBITORS SOS1, SOS2, SAV1 KIF11 2975/4885GLA 1947/4885POLB 3766/4885
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 KIF11 4867/4885GLA 893/4885POLB 3902/4885
US-20210188857-A1 SOS1 INHIBITORS SOS1, SOS2, SOST KIF11 3202/4885GLA 1861/4885POLB 4505/4885
US-12258366-B2 Bicyclic heteroaryl compounds and uses thereof SOST, SOS1, SOS2 KIF11 4867/4885GLA 893/4885POLB 3902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.